The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Subcutaneous Compared with Intravenous Epoetin in Patients Receiving Hemodialysis
Open accessAbstract
BACKGROUND: Several studies have suggested that if recombinant human erythropoietin (epoetin) is administered subcutaneously rather than intravenously, a lower dose may be sufficient to maintain the hematocrit at a given level. METHODS: In a randomized, unblinded trial conducted at 24 hemodialysis units at Veterans Affairs medical centers, we assigned 208 patients who were receiving long-term hemodialysis and epoetin therapy to treatment with either subcutaneous or intravenous epoetin. The dose was initially reduced until the hematocrit was below 30 percent and then was gradually increased to a level that would maintain the hematocrit in the range of 30 to 33 percent for 26 weeks. We compared the average doses in the 26-week maintenance phase and the discomfort associated with the two routes of administration. RESULTS: For the 107 patients treated by the subcutaneous route, the average weekly dose of epoetin during the maintenance phase was 32 percent less than that for the 101 patients treated by the intravenous route (mean [+/-SD], 95.1+/-75.0 vs. 140.3+/-88.5 U per kilogram of body weight per week; P<0.001). Only one patient in the subcutaneous-therapy group withdrew from the study because of pain at the injection site, and 86 percent rated the pain associated with subcutaneous administration as ranging from absent to mild. CONCLUSIONS: In patients receiving hemodialysis, subcutaneous administration of epoetin can maintain the hematocrit in a desired target range, with an average weekly dose of epoetin that is lower than with intravenous administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Statistical Methods for the Analysis of Biomedical Data
Ziegel, E., & Woolson, R. F. (1989) · Technometrics · doi:10.2307/1268847 · Cited by 583
Rao, D. S., Shih, M.-S., & Mohini, R. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280304 · Cited by 390
Ifudu, O., Feldman, J., & Friedman, E. A. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602153340702 · Cited by 253
Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta
Halstenson, C. E., Macres, M., Katz, S. A., Schnieders, J. R., Watanabe, M., Sobota, J. T., & Abraham, P. A. (1991) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1991.210 · Cited by 198
Macdougall, I. C., Hutton, R. D., Cavill, I., Coles, G. A., & Williams, J. D. (1989) · BMJ · doi:10.1136/bmj.299.6692.157 · Cited by 186
McMahon, F., Vargas, R., Ryan, M., Jain, A., Abels, R., Perry, B., & Smith, I. (1990) · Blood · doi:10.1182/blood.v76.9.1718.1718 · Cited by 179
Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease
Besarab, A., Flaharty, K. K., Erslev, A. J., McCrea, J. B., Vlasses, P. H., Medina, F. F. C., Caro, J., & Morris, E. M. (1992) · Journal of the American Society of Nephrology · doi:10.1681/asn.v291405 · Cited by 137
Salmonson, T., Danielson, B., & Wíkström, B. (1990) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1990.tb03692.x · Cited by 96
Intravenous versus subcutaneous dosing of Epoetin alfa in hemodialysis patients
Paganini, E. P., Eschbach, J. W., Lazarus, J. M., Stone, J. C. V., Gimenez, L. F., Gräber, S. E., Egrie, J. C., Okamoto, D. M., & Goodkin, D. A. (1995) · American Journal of Kidney Diseases · doi:10.1016/0272-6386(95)90654-1 · Cited by 67
Cited by
Erythropoietin: Physiology and Pharmacology Update
Fisher, J. W. (2003) · Experimental Biology and Medicine · doi:10.1177/153537020322800101 · Cited by 708
Pure Red-Cell Aplasia and Epoetin Therapy
Bennett, C. L., Luminari, S., Nissenson, A. R., Tallman, M. S., Klinge, S. A., McWilliams, N., McKoy, J. M., Kim, B., Lyons, E. A., Trifilio, S. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040528 · Cited by 437
Rizzo, J. D., Lichtin, A. E., Woolf, S. H., Seidenfeld, J., Bennett, C. L., Cella, D., Djulbegovic, B., Goode, M. J., Jakubowski, A. A., Lee, S. J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.177 · Cited by 417
IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000
(2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(01)70008-x · Cited by 400
Pisoni, R. L., Bragg-Gresham, J. L., Young, E. W., Akizawa, T., Asano, Y., Locatelli, F., Bommer, J., Cruz, J. M., Kerr, P. G., Mendelssohn, D. C., et al. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.03.023 · Cited by 391
Metadata
- Authors
- Kaufman, J. S., Reda, D. J., Fye, C. L., Goldfarb, D. S., Henderson, W. G., Kleinman, J. G., & Vaamonde, C. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1998-08-27
- Volume
- 339
- Issue
- 9
- Pages
- 578-583
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2321111200
- Cited by
- 300
- References
- 15
- FWCI
- 8.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Subcutaneous Compared with Intravenous Epoetin in Patients Receiving Hemodialysis. https://app.cochat.ai/papers/10.1056/nejm199808273390902
- The paper
- Kaufman, J. S., Reda, D. J., Fye, C. L., Goldfarb, D. S., Henderson, W. G., Kleinman, J. G., & Vaamonde, C. A. (1998). Subcutaneous Compared with Intravenous Epoetin in Patients Receiving Hemodialysis. New England Journal of Medicine. https://doi.org/10.1056/nejm199808273390902
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.